

Total returns[†]

| At 31 Jul 2024 | 1 Mth | 3 Mths | 1 Yr | 3 Yrs | 5 Yrs | 10 Yrs | Incep % p.a. |
|--|-------|--------|-------|--------|--------|--------|--------------|
| | % | % | % | % p.a. | % p.a. | % p.a. | (Dec 2000) |
| OC Premium Small Companies Fund | 2.6 | 3.6 | 12.7 | 4.1 | 7.4 | 9.6 | 10.6 |
| S&P/ASX Small Ordinaries Accumulation | 3.5 | 2.0 | 9.3 | (0.6) | 3.5 | 6.3 | 5.7 |
| Outperformance | (0.9) | 1.6 | 3.4 | 4.7 | 3.9 | 3.3 | 4.8 |
| S&P/ASX Small Industrials Accumulation | 5.1 | 5.7 | 12.7 | (0.3) | 3.1 | 6.7 | 6.0 |
| Outperformance | (2.5) | (2.1) | (0.0) | 4.3 | 4.3 | 2.9 | 4.5 |

Performance review

The Small-Cap recovery continued in July with the OC Premium Small Companies Fund finishing the month up +2.6%. The Fund was behind both the S&P/ASX Small Ordinaries Accumulation Index and the S&P/ASX Small Industrials Accumulation Index which were up +3.5% and +5.1%, respectively, in a strong start to the new financial year.

Recent portfolio addition IRESS (IRE, +27.5%) traded sharply higher, with the progress on their turnaround illustrated by the pre-announcement of FY24 EBITDA growth of 50%, triggering analyst upgrades. Pinnacle Investment Management (PNI, +15.7%) rallied into its full year result as investors became more comfortable with the material growth opportunity offered by new UK boutique Life Cycle Investment Partners, and with strong equity markets driving affiliate FUM growth across the group. There were few material underperformers in the Fund during July, although data centre exposures NextDC (NXT, -5.0%) and Infratil (IFT, -3.8%) took a breather, following the lead of US companies exposed to the AI thematic which also saw profit taking during the month.

Outlook

The soft landing narrative in the US, which had become the consensus view amongst market participants, has been called into question by two key weak data points over the past week. Firstly, the Institute of Supply Management (ISM) survey printed weak, with new orders and employment components well behind expectations. And then fears of a US recession surged following the release of weak employment data the following day, triggering a closely watched recession indicator known as the "Sahm Rule". The jobless rate in July rose to 4.3%, ticking the three-month moving average of US unemployment more than 0.5% above the 3.6% average from one year ago. Historically, this rule being triggered has been a harbinger that the US economy has tipped into recession.


In response, the market mood changed abruptly and stocks sold off heavily at the start of August. The sell-off has been intensified by a swift reversal of the long-standing 'yen carry trade' where investors borrow low interest Japanese Yen to invest in higher-yielding, non-Yen denominated, global assets. This reversal was driven by concerns over a potential US recession, leading traders to anticipate a quicker rate-cutting cycle from the US Federal Reserve (the 'Fed'). OC cautions that

short term economic data can be 'noisy' and with a Fed rate cut (potentially 50 basis points according to some commentators) a near certainty at the September Fed meeting, we are yet to make any major changes to our portfolio.

On a positive note, trimmed mean inflation, the RBA's preferred measure of price pressures, moderated to 3.9% in the June quarter. The unemployment rate also ticked higher to 4.1% in June. Coupled with developments offshore, these data points were sufficient for the RBA to hold rates steady in August, although their commentary remains hawkish.

Looking ahead, the OC Funds investment team will be focussed on August reporting season. The Fund has a solid cash buffer of around 12% leaving us well positioned to either capitalise on any protracted stock sell off or, alternatively, deploy cash into new or existing stock ideas that look compelling following the release of their results.

Performance Comparison of \$100,000 over 10 yrs*



Top 5 holdings#

| Company | ASX Code |
|-------------------------------|----------|
| GQG Partners Inc. | GQG |
| HMC Capital Limited | HMC |
| Mineral Resources Limited | MIN |
| Seven Group Holdings Limited | SVW |
| Telix Pharmaceuticals Limited | TLX |

[#]The top 5 portfolio holdings are in alphabetical order and may not be representative of current or future investments.





Key Facts

Fund Overview

The Fund is a long-only, benchmark-unaware unit trust. It primarily invests in 30 to 50 quality small to medium-sized Australian companies with sustainable business models, quality management and attractive investment fundamentals that are listed, or about to list, on the ASX.

Responsible entity

Copia Investment Partners

Inception date

December 2000

Benchmark

S&P/ASX Small Ordinaries Accumulation Index

Investment time frame

At least 5 years

Distribution

Half-yearly

Management fee

1.20% p.a. (including GST net of RITC)

Performance fee

20.5% (including GST net of RITC) of the amount the Fund outperforms its benchmark provided specific conditions are met including a minimum absolute 5% return.

Performance hurdle

S&P/ASX Small Ordinaries Accumulation Index

High-water mark

Yes

Typical Investment Exposure

 Cash
 0%-20%

 Equities
 80%-100%

 Including:
 S&P/ASX 100 Constituents
 0%-20%

Diatforms

AMP MyNorth | Grow Wrap | Asgard | BT Panorama | CFS First Choice | CFS First Wrap | Hub 24 | Insignia (Expand) | Xplore (Linear) | Macquarie | MLC/Navigator | Netwealth | OneVue | Powerwrap | Praemium | DASH | Mason Stevens









CONTACT COPIA

1800 442 129 | clientservices@copiapartners.com.au | copiapartners.com.au

[†]The total return performance figures quoted are historical, calculated using end-of-month hard-close mid-prices and do not allow for the effects of income tax or inflation. Total returns assume the reinvestment of all distributions. The performance is quoted net of all fees and expenses. The index does not incur these costs. This information is provided for general comparative purposes. ^{*}The performance comparison of \$100,000 over 10 years is for illustrative purposes only. All returns shown are based on Australian dollar figures. Past performance is not a reliable indicator of future performance. The total returns shown are prepared on an ongoing basis (i.e. they include all ongoing fees and expenses and assume reinvestment of all distributions). They do not take personal taxation into account. The comparison with the S&P/ASX Small Ordinaries Accumulation Index is for comparative purposes only. Index returns do not allow for transactional, management, operational or tax costs. An index is not managed and investors cannot invest directly in an index.

Past performance is not a reliable indicator of future performance. Positive returns, which the OC Premium Small Companies Fund (the Fund) is designed to

Past performance is not a reliable indicator of future performance. Positive returns, which the OC Premium Small Companies Fund (the Fund) is designed to provide, are different regarding risk and investment profile to index returns. A performance fee of 20.5% is payable annually on any excess performance (after deducting the management fee) above the benchmark, S&P/ASX Small Ordinaries Accumulation Index, to 30 June. A performance fee is only payable where the Fund has returned 5% or more since the last performance fee was paid. This document is for general information purposes only and does not take into account the specific investment objectives, financial situation or particular needs of any specific reader. As such, before acting on any information contained in this article, readers should consider the appropriateness of the information to their needs. This may involve seeking advice from a qualified financial adviser. Copia Investment Partners Ltd (AFSL 229316, ABN 22 092 872 056) (Copia) is the issuer of the OC Premium Small Companies Fund (ARSN 098 644 976). A current PDS is available from Copia located at Level 47, 80 Collins Street (North Tower), Melbourne VIC 3000, by visiting ocfunds.copiapartners.com.au or by calling 1800 442 129 (free call). A person should consider the PDS before deciding whether to acquire or continue to hold an interest in the Fund. Any opinions or recommendation contained in this document are subject to change without notice and Copia is under no obligation to update or keep any information contained in this document current.

The rating issued October 2022 APIR OPS0002AU is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2022 Lonsec. All rights reserved.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned APIR OPS0002AU— February 2023) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at http://www.zenithpartners.com.au/RegulatoryGuidelines



